Clinical trials: Refractory Endometrial Serous Adenocarcinoma
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not…
- Conditions
- Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT03924245
- Testing
- Entinostat, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT03660826
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 761 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Endometrial Cancer
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or…
- Trial name
- NCT00022620
- Testing
- paclitaxel
- Where
- 8 sites in Austria, Belgium and 4 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC